



## Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies

The **New York State Neurological Society (NYSNS)** invites you to attend an AMA - certified live webinar titled, “Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies.” Neurologists need to modify their clinical approach to provide individualized care within the context of new treatments. The number of adults with SMA is expected to continue to grow, and thus, a greater need exists for clinicians to improve their provision of age-appropriate care and ensure adults benefit from therapeutic advances. This educational initiative will provide targeted, clear, and concise information that would help neurologists provide optimal, individualized care to their adult patients with SMA.

**Thursday, May 9, 2024**

Live Virtual Meeting

**6:30 PM – 7:30 PM**

### **FACULTY**

**Perry Shieh, MD, PhD**

Professor (Health Sciences)

Departments of Neurology and Pediatrics

David Geffen School of Medicine at UCLA

University of California, Los Angeles

Los Angeles, California

For full accreditation information and to register, click here or go to: [www.clinicaloptions.com/SMA2023](http://www.clinicaloptions.com/SMA2023)

### **Agenda**

- SMA overview, SMA type IV
- Disease burden, clinical and psychosocial impact
  - Adult specific factors to consider – occupational/career, family planning
- Treatment options
  - Safety and efficacy of available and emerging treatments for adults with SMA
    - Risdiplam, nusinersen
    - Clinical updates of note
  - Psychosocial support for patients with SMA
- Factors to consider when developing/modifying treatment plans
  - Goals, disease progression
  - Patient factors/preferences
  - Patient engagement: How to foster this (shared decision-making, communication strategies)
  - Case example(s)

**Target Audience:** The intended audience for this educational initiative is neurologists who manage patients with spinal muscular atrophy.

### **Learning Objectives:**

Upon completion of this activity, learners should be able to:

- Discuss the unique clinical issues and psychosocial needs faced by adults with SMA

- Assess the latest safety and efficacy data of available and emerging disease-modifying therapies for SMA in adults
- Integrate available disease-modifying therapies for SMA into individualized, evidence-based treatment plans
- Apply effective communication strategies to engage patients in shared decision making and reach management decisions that meet their individual needs

#### Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Cure SMA. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Disclosures will be made known to learners before the activity.

Provided by Clinical Care Options, LLC, in partnership with Cure SMA.

Supported by educational grants from Biogen and Genentech, a member of the Roche Group.

***We invite you to share this event with your colleagues by forwarding this email.***

---

Provided by Clinical Care Options, LLC, in partnership with Cure SMA.

Supported by educational grants from Biogen and Genentech, a member of the Roche Group.

---



© 2023 Clinical Care Options, LLC All rights reserved. 12001 Sunrise Valley Drive, Suite 300, Reston, VA 20191

To ensure you receive Clinical Care Options educational materials by email, please add [info@e.mycea.com](mailto:info@e.mycea.com) to your contacts or address book. Click to [update your email preferences or unsubscribe](#) from all communication.

[Not a member yet?](#)